EUVIMEDEUVIMED entdecken
Crossref

Selective BET inhibitor RVX ‐208 ameliorates periodontal inflammation and bone loss

Mingxu Sun, Nicholas Clayton, Sheikh Alam, Niels Asmussen, Andrew Wong, Jin Ha Kim, Gary Luong, Sasan Mokhtari, David Pellei, Caroline K Carrico, Zvi Schwartz, Barbara D Boyan und 3 weitere

Journal of Clinical Periodontology · 2023

DOI: 10.1111/jcpe.13887 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Periodontology, 2023. Verfasst von Mingxu Sun und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Periodontics, School of Dentistry, Virginia Commonwealth University, Richmond, Virginia, USA. Hauptthemen laut MEDLINE: Alveolar Bone Loss, Periodontitis. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: NIDCR NIH HHS, National Institutes of Health, Virginia Commonwealth University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

To determine the effects of RVX‐208, a selective bromodomain and extra‐terminal domain (BET) inhibitor targeting bromodomain 2 (BD2), on periodontal inflammation and bone loss. Materials and Methods Macrophage‐like cells (RAW264.7) and human gingival epithelial cells were challenged by Porphyromonas gingivalis ( Pg ) with or without RVX‐208. Inflammatory gene expression and cytokine production were measured by reverse transcription polymerase chain reaction and enzyme‐linked immunosorbent assay, respectively. RAW264.7 cells were induced to osteoclast differentiation. After RVX‐208 treatment, osteoclast differentiation was evaluated by histology, tartrate‐resistant‐acid‐phosphatase (TRAP) activity and the expression of osteoclast‐specific genes. The effect of RVX‐208 on osteoclast transcriptome was studied by RNA sequencing. Periodontitis was induced in rats by ligature and local RVX‐208 treatment was administered every other day. Alveolar bone loss was measured by micro‐computed tomography.

Results

RVX‐208 inhibited inflammatory gene expression and cytokine production in Pg ‐infected cells. Osteoclast differentiation was inhibited by RVX‐208, as evidenced by reduced osteoclast number, TRAP activity and osteoclast‐specific gene expression. RVX‐208 displayed a more selective and less profound suppressive impact on transcriptome compared with pan‐BET inhibitor, JQ1. RVX‐208 administration prevented the alveolar bone loss in vivo.

Conclusions

RVX‐208 regulated both upstream (inflammatory cytokine production) and downstream (osteoclast differentiation) events that lead to periodontal tissue destruction, suggesting that it may be a promising ‘epi‐drug’ for the prevention of periodontitis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alveolar Bone LossPeriodontitisRatsHumansAnimalsX-Ray MicrotomographyInflammationOsteoclastsCytokinesQuinazolinones

Stichwörter der Autor:innen

BET inhibitorRVX-208histone acetylationosteoclastperiodontitis

Substanzen

CytokinesapabetaloneQuinazolinones

Autor:innen und Institutionen

  • Department of Periodontics, School of Dentistry, Virginia Commonwealth University, Richmond, Virginia, USA.
  • Jianbo Dental Clinic, Qingdao, People's Republic of China.
  • Department of Biomedical Engineering, Virginia Commonwealth University, Richmond, Virginia, USA.
  • Department of Dental Public Health and Policy, School of Dentistry, Virginia Commonwealth University, Richmond, Virginia, USA.
  • Department of Oral Medicine, Infection, and Immunity, Harvard School of Dental Medicine, Boston, Massachusetts, USA.
  • Department of Periodontics, School of Dental Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.

Förderung

  • NIDCR NIH HHS
  • National Institutes of Health
  • Virginia Commonwealth University

Zitieren

APA

Sun, M., Clayton, N., Alam, S., Asmussen, N., Wong, A., Kim, J. H., Luong, G., Mokhtari, S., Pellei, D., Carrico, C. K., Schwartz, Z., Boyan, B. D., Giannobile, W. V., Sahingur, S. E., & Lin, Z. (2023). Selective BET inhibitor RVX ‐208 ameliorates periodontal inflammation and bone loss. Journal of Clinical Periodontology. https://doi.org/10.1111/jcpe.13887

Vancouver

Sun M, Clayton N, Alam S, Asmussen N, Wong A, Kim JH, et al. Selective BET inhibitor RVX ‐208 ameliorates periodontal inflammation and bone loss. Journal of Clinical Periodontology. 2023. doi:10.1111/jcpe.13887

BibTeX
@article{Sun2023,
  author = {Sun, Mingxu and Clayton, Nicholas and Alam, Sheikh and Asmussen, Niels and Wong, Andrew and Kim, Jin Ha and Luong, Gary and Mokhtari, Sasan and Pellei, David and Carrico, Caroline K and Schwartz, Zvi and Boyan, Barbara D and Giannobile, William V and Sahingur, Sinem Esra and Lin, Zhao},
  title = {Selective BET inhibitor RVX ‐208 ameliorates periodontal inflammation and bone loss},
  journal = {Journal of Clinical Periodontology},
  year = {2023},
  doi = {10.1111/jcpe.13887}
}
Kostenlos starten →